

STATE OF OKLAHOMA

2nd Session of the 57th Legislature (2020)

SENATE BILL 1146

By: Standridge

AS INTRODUCED

An Act relating to the Uniform Controlled Dangerous Substances Act; amending 63 O.S. 2011, Section 2-204, as last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 2019, Section 2-204), which relates to Schedule I; amending 63 O.S. 2011, Section 2-210, as last amended by Section 4, Chapter 390, O.S.L. 2017 (63 O.S. Supp. 2019, Section 2-210), which relates to Schedule IV; modifying inclusions; and providing an effective date.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. AMENDATORY 63 O.S. 2011, Section 2-204, as last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 2019, Section 2-204), is amended to read as follows:

Section 2-204. The controlled substances listed in this section are included in Schedule I and include any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, when the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation.

1 A. Any of the following opiates, including their isomers,
2 esters, ethers, salts, and salts of isomers, esters, and ethers,
3 unless specifically excepted, when the existence of these isomers,
4 esters, ethers, and salts is possible within the specific chemical
5 designation:

- 6 1. Acetylmethadol;
- 7 2. Allylprodine;
- 8 3. Alphacetylmethadol;
- 9 4. Alphameprodine;
- 10 5. Alphamethadol;
- 11 6. Benzethidine;
- 12 7. Betacetylmethadol;
- 13 8. Betameprodine;
- 14 9. Betamethadol;
- 15 10. Betaprodine;
- 16 11. Clonitazene;
- 17 12. Dextromoramide;
- 18 13. Dextrorphan (except its methyl ether);
- 19 14. Diampromide;
- 20 15. Diethylthiambutene;
- 21 16. Dimenoxadol;
- 22 17. Dimepheptanol;
- 23 18. Dimethylthiambutene;
- 24 19. Dioxaphetyl butyrate;

- 1 20. Dipipanone;
- 2 21. Ethylmethythiambutene;
- 3 22. Etonitazene;
- 4 23. Etoxeridine;
- 5 24. Furethidine;
- 6 25. Hydroxypethidine;
- 7 26. Ketobemidone;
- 8 27. Levomoramide;
- 9 28. Levophenacylmorphane;
- 10 29. Morpheridine;
- 11 30. Noracymethadol;
- 12 31. Norlevorphanol;
- 13 32. Normethadone;
- 14 33. Norpipanone;
- 15 34. Phenadoxone;
- 16 35. Phenampromide;
- 17 36. Phenomorphan;
- 18 37. Phenoperidine;
- 19 38. Piritramide;
- 20 39. Proheptazine;
- 21 40. Properidine;
- 22 41. Racemoramide; or
- 23 42. Trimeperidine.
- 24
- 25

1 B. Any of the following opium derivatives, their salts,
2 isomers, and salts of isomers, unless specifically excepted, when
3 the existence of these salts, isomers, and salts of isomers is
4 possible within the specific chemical designation:

- 5 1. Acetorphine;
- 6 2. Acetyldihydrocodeine;
- 7 3. Benzylmorphine;
- 8 4. Codeine methylbromide;
- 9 5. Codeine-N-Oxide;
- 10 6. Cyprenorphine;
- 11 7. Desomorphine;
- 12 8. Dihydromorphine;
- 13 9. Etorphine;
- 14 10. Heroin;
- 15 11. Hydromorphenol;
- 16 12. Methyldesorphine;
- 17 13. Methylhydromorphine;
- 18 14. Morphine methylbromide;
- 19 15. Morphine methylsulfonate;
- 20 16. Morphine-N-Oxide;
- 21 17. Myrophine;
- 22 18. Nicocodeine;
- 23 19. Nicomorphine;
- 24 20. Normorphine;

21. Phoclodine;
22. Thebacon;
23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
(Acetyl fentanyl);
24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
(Crotonyl fentanyl);
25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
furancarboxamide (Furanyl fentanyl);
26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
27. N-(1-phenethylpiperidin-4-yl)-N-
phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
(Butyl fentanyl).

C. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

1. Methcathinone;
2. 3, 4-methylenedioxy amphetamine;
3. 3, 4-methylenedioxy methamphetamine;
4. 5-methoxy-3, 4-methylenedioxy amphetamine;
5. 3, 4, 5-trimethoxy amphetamine;
6. Bufotenine;

- 1 7. Diethyltryptamine;
- 2 8. Dimethyltryptamine;
- 3 9. 4-methyl-2, 5-dimethoxyamphetamine;
- 4 10. Ibogaine;
- 5 11. Lysergic acid diethylamide;
- 6 12. Marihuana;
- 7 13. Mescaline;
- 8 14. N-benzylpiperazine;
- 9 15. N-ethyl-3-piperidyl benzilate;
- 10 16. N-methyl-3-piperidyl benzilate;
- 11 17. Psilocybin;
- 12 18. Psilocyn;
- 13 19. 2, 5 dimethoxyamphetamine;
- 14 20. 4 Bromo-2, 5-dimethoxyamphetamine;
- 15 21. 4 methoxyamphetamine;
- 16 22. Cyclohexamine;
- 17 23. Salvia Divinorum;
- 18 24. Salvinorin A;
- 19 25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
- 20 thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
- 21 TCP, TCP, Tenocyclidine;
- 22 26. Phencyclidine (PCP);
- 23 27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
- 24 Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;

28. 1-(3-trifluoromethylphenyl) piperazine;
29. Flunitrazepam;
30. B-hydroxy-amphetamine;
31. B-ketoamphetamine;
32. 2,5-dimethoxy-4-nitroamphetamine;
33. 2,5-dimethoxy-4-bromophenethylamine;
34. 2,5-dimethoxy-4-chlorophenethylamine;
35. 2,5-dimethoxy-4-iodoamphetamine;
36. 2,5-dimethoxy-4-iodophenethylamine;
37. 2,5-dimethoxy-4-methylphenethylamine;
38. 2,5-dimethoxy-4-ethylphenethylamine;
39. 2,5-dimethoxy-4-fluorophenethylamine;
40. 2,5-dimethoxy-4-nitrophenethylamine;
41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
43. 2,5-dimethoxy-4-propylthio-phenethylamine;
44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
47. 5-methoxy-N, N-dimethyltryptamine;
48. N-methyltryptamine;
49. A-ethyltryptamine;
50. A-methyltryptamine;
51. N, N-diethyltryptamine;

52. N, N-diisopropyltryptamine;
53. N, N-dipropyltryptamine;
54. 5-methoxy-a-methyltryptamine;
55. 4-hydroxy-N, N-diethyltryptamine;
56. 4-hydroxy-N, N-diisopropyltryptamine;
57. 5-methoxy-N, N-diisopropyltryptamine;
58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
59. 3,4-Methylenedioxyethcathinone (Methylone);
60. 3,4-Methylenedioxypropylone (MDPV);
61. 4-Methylmethcathinone (Mephedrone);
62. 4-methoxymethcathinone;
63. 4-Fluoromethcathinone;
64. 3-Fluoromethcathinone;
65. 1-(8-bromobenzo 1,2-b;4,5-b' difuran-4-yl)-2-aminopropane;
66. 2,5-Dimethoxy-4-chloroamphetamine;
67. 4-Methylethcathinone;
68. Pyrovalerone;
69. N,N-diallyl-5-methoxytryptamine;
70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
71. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
72. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
73. Alpha-Pyrrolidinopentiophenone;
74. 4-Fluoroamphetamine;
75. Pentedrone;

- 1 76. 4'-Methyl-a-pyrrolidinohexaphenone;
- 2 77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
- 3 78. 2,5-dimethoxyphenethylamine;
- 4 79. 1,4-Dibenzylpiperazine;
- 5 80. N,N-Dimethylamphetamine;
- 6 81. 4-Fluoromethamphetamine;
- 7 82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
- 8 (25C-NBOMe);
- 9 83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
- 10 (25I-NBOMe);
- 11 84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
- 12 (25B-NBOMe);
- 13 85. 1-(4-Fluorophenyl)piperazine;
- 14 86. Methoxetamine;
- 15 87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
- 16 methylbenzamide;
- 17 88. N-ethyl hexadrone;
- 18 89. Isopropyl-U-47700;
- 19 90. Para-fluorobutyl fentanyl;
- 20 91. Fluoro isobutryl fentanyl;
- 21 92. 3-Hydroxy Phencyclidine (PCP); ~~or~~
- 22 93. 3-methoxy Phencyclidine (PCP); i
- 23 94. Flualprazolam; or
- 24 95. Flubromazolam.
- 25

1 D. Unless specifically excepted or unless listed in a different
2 schedule, any material, compound, mixture, or preparation which
3 contains any quantity of the following substances having stimulant
4 or depressant effect on the central nervous system:

5 1. Fenethylline;

6 2. Mecloqualone;

7 3. N-ethylamphetamine;

8 4. Methaqualone;

9 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
10 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
11 oxybate, and sodium oxybutyrate;

12 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
13 manufactured or promoted for human consumption, with the exception
14 of legitimate food additive and manufacturing purposes;

15 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
16 manufactured for human consumption, with the exception of legitimate
17 food additive and manufacturing purposes;

18 8. Gamma Valerolactone (GVL) as packaged, marketed, or
19 manufactured for human consumption, with the exception of legitimate
20 food additive and manufacturing purposes;

21 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
22 manufactured, or promoted for human consumption with the exception
23 of legitimate manufacturing purposes; or

24 10. N-ethylpentylone.

1 E. 1. The following industrial uses of Gamma-Butyrolactone,
2 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
3 excluded from all schedules of controlled substances under this
4 title:

- 5 a. pesticides,
- 6 b. photochemical etching,
- 7 c. electrolytes of small batteries or capacitors,
- 8 d. viscosity modifiers in polyurethane,
- 9 e. surface etching of metal coated plastics,
- 10 f. organic paint disbursements for water soluble inks,
- 11 g. pH regulators in the dyeing of wool and polyamide
12 fibers,
- 13 h. foundry chemistry as a catalyst during curing,
- 14 i. curing agents in many coating systems based on
15 urethanes and amides,
- 16 j. additives and flavoring agents in food, confectionary,
17 and beverage products,
- 18 k. synthetic fiber and clothing production,
- 19 l. tetrahydrofuran production,
- 20 m. gamma butyrolactone production,
- 21 n. polybutylene terephthalate resin production,
- 22 o. polyester raw materials for polyurethane elastomers
23 and foams,
- 24 p. coating resin raw material, and

1 q. as an intermediate in the manufacture of other
2 chemicals and pharmaceuticals.

3 2. At the request of any person, the Director may exempt any
4 other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
5 Gamma Valerolactone~~7~~ or 1,4 Butanediol from being included as a
6 Schedule I controlled substance if such product is labeled,
7 marketed, manufactured and distributed for legitimate industrial use
8 in a manner that reduces or eliminates the likelihood of abuse.

9 3. In making a determination regarding an industrial product,
10 the Director, after notice and hearing, shall consider the
11 following:

- 12 a. the history and current pattern of abuse,
- 13 b. the name and labeling of the product,
- 14 c. the intended manner of distribution, advertising and
15 promotion of the product, and
- 16 d. other factors as may be relevant to and consistent
17 with the public health and safety.

18 4. The hearing shall be held in accordance with the procedures
19 of the Administrative Procedures Act.

20 F. Any material, compound, mixture~~7~~ or preparation, whether
21 produced directly or indirectly from a substance of vegetable origin
22 or independently by means of chemical synthesis, or by a combination
23 of extraction and chemical synthesis, that contains any quantity of
24 the following substances, or that contains any of their salts,

1 isomers, and salts of isomers when the existence of these salts,
2 isomers, and salts of isomers is possible within the specific
3 chemical designation:

- 4 1. JWH-004;
- 5 2. JWH-007;
- 6 3. JWH-009;
- 7 4. JWH-015;
- 8 5. JWH-016;
- 9 6. JWH-018;
- 10 7. JWH-019;
- 11 8. JWH-020;
- 12 9. JWH-030;
- 13 10. JWH-046;
- 14 11. JWH-047;
- 15 12. JWH-048;
- 16 13. JWH-049;
- 17 14. JWH-050;
- 18 15. JWH-070;
- 19 16. JWH-071;
- 20 17. JWH-072;
- 21 18. JWH-073;
- 22 19. JWH-076;
- 23 20. JWH-079;
- 24 21. JWH-080;

1	22.	JWH-081;
2	23.	JWH-082;
3	24.	JWH-094;
4	25.	JWH-096;
5	26.	JWH-098;
6	27.	JWH-116;
7	28.	JWH-120;
8	29.	JWH-122;
9	30.	JWH-145;
10	31.	JWH-146;
11	32.	JWH-147;
12	33.	JWH-148;
13	34.	JWH-149;
14	35.	JWH-150;
15	36.	JWH-156;
16	37.	JWH-167;
17	38.	JWH-175;
18	39.	JWH-180;
19	40.	JWH-181;
20	41.	JWH-182;
21	42.	JWH-184;
22	43.	JWH-185;
23	44.	JWH-189;
24	45.	JWH-192;

1	46.	JWH-193;
2	47.	JWH-194;
3	48.	JWH-195;
4	49.	JWH-196;
5	50.	JWH-197;
6	51.	JWH-198;
7	52.	JWH-199;
8	53.	JWH-200;
9	54.	JWH-201;
10	55.	JWH-202;
11	56.	JWH-203;
12	57.	JWH-204;
13	58.	JWH-205;
14	59.	JWH-206;
15	60.	JWH-207;
16	61.	JWH-208;
17	62.	JWH-209;
18	63.	JWH-210;
19	64.	JWH-211;
20	65.	JWH-212;
21	66.	JWH-213;
22	67.	JWH-234;
23	68.	JWH-235;
24	69.	JWH-236;

1	70.	JWH-237;
2	71.	JWH-239;
3	72.	JWH-240;
4	73.	JWH-241;
5	74.	JWH-242;
6	75.	JWH-243;
7	76.	JWH-244;
8	77.	JWH-245;
9	78.	JWH-246;
10	79.	JWH-248;
11	80.	JWH-249;
12	81.	JWH-250;
13	82.	JWH-251;
14	83.	JWH-252;
15	84.	JWH-253;
16	85.	JWH-262;
17	86.	JWH-292;
18	87.	JWH-293;
19	88.	JWH-302;
20	89.	JWH-303;
21	90.	JWH-304;
22	91.	JWH-305;
23	92.	JWH-306;
24	93.	JWH-307;

1	94.	JWH-308;
2	95.	JWH-311;
3	96.	JWH-312;
4	97.	JWH-313;
5	98.	JWH-314;
6	99.	JWH-315;
7	100.	JWH-316;
8	101.	JWH-346;
9	102.	JWH-348;
10	103.	JWH-363;
11	104.	JWH-364;
12	105.	JWH-365;
13	106.	JWH-367;
14	107.	JWH-368;
15	108.	JWH-369;
16	109.	JWH-370;
17	110.	JWH-371;
18	111.	JWH-373;
19	112.	JWH-386;
20	113.	JWH-387;
21	114.	JWH-392;
22	115.	JWH-394;
23	116.	JWH-395;
24	117.	JWH-397;

1	118.	JWH-398;
2	119.	JWH-399;
3	120.	JWH-400;
4	121.	JWH-412;
5	122.	JWH-413;
6	123.	JWH-414;
7	124.	JWH-415;
8	125.	CP-55, 940;
9	126.	CP-47, 497;
10	127.	HU-210;
11	128.	HU-211;
12	129.	WIN-55, 212-2;
13	130.	AM-2201;
14	131.	AM-2233;
15	132.	JWH-018 adamantyl-carboxamide;
16	133.	AKB48;
17	134.	JWH-122 N-(4-pentenyl) analog;
18	135.	MAM2201;
19	136.	URB597;
20	137.	URB602;
21	138.	URB754;
22	139.	UR144;
23	140.	XLR11;
24	141.	A-796,260;

- 1 142. STS-135;
2 143. AB-FUBINACA;
3 144. AB-PINACA;
4 145. PB-22;
5 146. AKB48 N-5-Fluoropentyl;
6 147. AM1248;
7 148. FUB-PB-22;
8 149. ADB-FUBINACA;
9 150. BB-22;
10 151. 5-Fluoro PB-22; or
11 152. 5-Fluoro AKB-48.

12 G. In addition to those substances listed in subsection F of
13 this section, unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or preparation
15 which contains any quantity of a synthetic cannabinoid found to be
16 in any of the following chemical groups:

17 1. Naphthoylindoles: any compound containing a 3-(1-
18 naphthoyl)indole structure with or without substitution at the
19 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
21 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
22 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
23 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
24 halophenyl group, whether or not further substituted on the indole

ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthoylindoles include, but are not limited to:

- a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200),
- b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
- c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
- d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
- e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
- f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
- g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
- h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
- i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
- j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
- k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
- l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
- m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole (JWH-098),
- n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
- o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)indole (AM-1220),
- p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201), or
- q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);

1 2. Naphthylmethylinroles: any compound containing a 1H-indol-3-
2 yl-(1-naphthyl)methane structure with or without substitution at the
3 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
5 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
6 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
7 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
8 halophenyl group, whether or not further substituted on the indole
9 ring to any extent, and whether or not substituted on the naphthyl
10 ring to any extent. Naphthylmethylinroles include, but are not
11 limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);

12 3. Naphthoylpyrroles: any compound containing a 3-(1-
13 naphthoyl)pyrrole structure with or without substitution at the
14 nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
15 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
16 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
17 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
18 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
19 phenyl, or halophenyl group, whether or not further substituted on
20 the pyrrole ring to any extent, and whether or not substituted on
21 the naphthyl group to any extent. Naphthoylpyrroles include, but
22 are not limited to:

23 a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
24
25

1 b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
2 (JWH-370),

3 c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or

4 d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);

5 4. Naphthylideneindenes: any compound containing a 1-(1-
6 naphthylmethylene)indene structure with or without substitution at
7 the 3-position of the indene ring by an alkyl, haloalkyl,
8 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
9 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
10 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
11 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
12 phenyl, or halophenyl group, whether or not further substituted on
13 the indene group to any extent, and whether or not substituted on
14 the naphthyl group to any extent. Naphthylmethylindenes include,
15 but are not limited to, (1-[(3-pentyl)-1H-inden-1-
16 ylidene)methyl]naphthalene (JWH-176);

17 5. Phenylacetylindoles: any compound containing a 3-
18 phenylacetylindole structure with or without substitution at the
19 nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
21 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
22 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
23 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
24 halophenyl group, whether or not further substituted on the indole

ring to any extent, and whether or not substituted on the phenyl ring to any extent. Phenylacetylindoles include, but are not limited to:

- a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
- b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8),
- c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
- d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
- e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
- f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);

6. Cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with or without substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, and whether or not further substituted on the cyclohexyl ring to any extent. Cyclohexylphenols include, but are not limited to:

- a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497),

- b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue), or
- c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);

7. Benzoylindoles: any compound containing a 3-(benzoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl group to any extent. Benzoylindoles include, but are not limited to:

- a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
- b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
- c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
- d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
- e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole (AM-2233);

1 8. Cyclopropoylindoles: Any compound containing a 3-
2 (cyclopropoyl)indole structure with substitution at the nitrogen
3 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
5 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
7 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
8 halophenyl group, whether or not further substituted in the indole
9 ring to any extent and whether or not substituted in the
10 cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
11 are not limited to:

- 12 a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
13 (UR-144),
- 14 b. 1-(5-chloropentyl)-3-(2,2,3,3-
15 tetramethylcyclopropoyl)indole (5Cl-UR-144), or
- 16 c. 1-(5-fluoropentyl)-3-(2,2,3,3-
17 tetramethylcyclopropoyl)indole (XLR11);

18 9. Indole Amides: Any compound containing a 1H-Indole-3-
19 carboxamide structure with or without substitution at the nitrogen
20 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
22 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
23 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
24 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or

halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Amides include, but are not limited to:

- a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (2NE1),
- b. N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135),
- c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA),
- d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
- e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (NNE1),
- f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide (5F-NNE1),
- g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
or
- h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006);

10. Indole Esters: Any compound containing a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to:

- a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22),
- b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22),
- c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22),
- d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22), or

e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201);

11. Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to:

a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone (AM1248), or

b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-001);

12. Carbazole Ketone: Any compound containing (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or

halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018);

13. Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl,

1 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

2 Benzimidazole Ketones include, but are not limited to:

- 3 a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
- 4 1)methanone (JWH-018 benzimidazole analog), or
- 5 b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
- 6 yl)(naphthalen-1-yl)methanone (FUBIMINA); and

7 14. Modified by Replacement: any compound defined in this
8 subsection that is modified by replacement of a carbon with nitrogen
9 in the indole, naphthyl, indene, benzimidazole, or carbazole ring.

10 SECTION 2. AMENDATORY 63 O.S. 2011, Section 2-210, as
11 last amended by Section 4, Chapter 390, O.S.L. 2017 (63 O.S. Supp.
12 2019, Section 2-210), is amended to read as follows:

13 Section 2-210. A. Any material, compound, mixture, or
14 preparation which contains any quantity of the following substances
15 having a potential for abuse associated with a stimulant or
16 depressant effect on the central nervous system:

- 17 1. Chloral betaine;
- 18 2. Chloral hydrate;
- 19 3. Ethchlorvynol;
- 20 4. Ethinamate;
- 21 5. Meprobamate;
- 22 6. Paraldehyde;
- 23 7. Petrichloral;
- 24 8. Diethylpropion;

- 1 9. Phentermine;
- 2 10. Pemoline;
- 3 11. Chlordiazepoxide;
- 4 12. Chlordiazepoxide and its salts, but not including
- 5 chlordiazepoxide hydrochloride and clidinium bromide or
- 6 chlordiazepoxide and water-soluble esterified estrogens;
- 7 13. Diazepam;
- 8 14. Oxazepam;
- 9 15. Clorazepate;
- 10 16. Flurazepam and its salts;
- 11 17. Clonazepam;
- 12 18. Barbitol;
- 13 19. Mebutamate;
- 14 20. Methohexital;
- 15 21. Methylphenobarbital;
- 16 22. Phenobarbital;
- 17 23. Fenfluramine;
- 18 24. Pentazocine;
- 19 25. Propoxyphene;
- 20 26. Butorphanol;
- 21 27. Alprazolam;
- 22 28. Halazepam;
- 23 29. Lorazepam;
- 24 30. Prazepam;

31. Temazepam;
32. Triazolam;
33. Carisoprodol;
34. Dichloralphenazone;
35. Estazolam;
36. Eszopiclone;
37. Midazolam;
38. Modafinil;
39. Zaleplon;
40. Zolpidem;
41. Tramadol;
42. Bromazepam;
43. Suvorexant;
44. Phenazepam;
45. Etizolam; ~~or~~
46. Clonazolam; or
47. Gabapentin.

B. 1. The following nonnarcotic substances, which may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301), be lawfully sold over the counter without a prescription, are excluded from all schedules of controlled substances under this title:

- a. Breathe-Aid,
- b. BronCare,

- c. Bronchial Congestion,
- d. Bronkaid Tablets,
- e. Bronkaid Dual Action Caplets,
- f. Bronkotabs,
- g. Bronkolixir,
- h. NeoRespin,
- i. Pazo Hemorrhoid Ointment and Suppositories,
- j. Primatene Tablets,
- k. Primatene "Dual Action" Formula,
- l. Quelidrine,
- m. Resp, and
- n. Vatronal Nose Drops.

2. At the request of any person, the Director may exempt any other drug product containing ephedrine from being included as a Schedule IV controlled substance if such product:

- a. is labeled and marketed in a manner consistent with the pertinent OTC tentative final or final monograph issued by the FDA, and
- b. is manufactured and distributed for legitimate medicinal use and in a manner that reduces or eliminates the likelihood of abuse.

3. In making a determination regarding a drug product, the Director, after notice and hearing, shall consider the following:

- a. the history and current pattern of abuse,

- 1 b. the name and labeling of the product,
2 c. the intended manner of distribution, advertising and
3 promotion of the product, and
4 d. other factors as may be relevant to and consistent
5 with the public health and safety.

6 4. The hearing shall be held in accordance with the
7 Administrative Procedures Act.

8 5. A list of current drug products meeting exemption
9 requirements under this subsection may be obtained from the Bureau
10 upon written request.

11 C. The Board of Pharmacy may except by rule any compound,
12 mixture, or preparation containing any depressant substance listed
13 in subsection A of this section from the application of all or any
14 part of the Uniform Controlled Dangerous Substances Act, Section 2-
15 101 et seq. of this title, if the compound, mixture, or preparation
16 contains one or more active medicinal ingredients not having a
17 depressant effect on the central nervous system, and if the
18 admixtures are included therein in combinations, quantity,
19 proportion, or concentration that vitiate the potential for abuse of
20 the substances which have a depressant effect on the central nervous
21 system.

22 SECTION 3. This act shall become effective November 1, 2020.
23

24 57-2-2560 BG 12/27/2019 10:30:54 AM
25